Leukotriene receptor antagonist combined with budesonide aerosol inhalation for children with cough variant asthma

Abstract

Objective To investigate the effect of leukotriene receptor antagonist combined with budesonide aerosol inhalation for children with cough variant asthma. Methods A total of 87 children with cough variant asthma treated at our hospital from January, 2015 to July, 2017 were divided into a control group (n=43) and an observation group (n=44) using random number table method. The control group were treated with budesonide aerosol inhalation; in addition, the observation group were treated with montelukast sodium. The clinical efficacy and pulmonary function indicators [forced expiratory volume in one second (FEV1), peak expiratory flow (PEF), the ratio of FEV1 to forced vital capacity (FEV1%)], peripheral blood eosinophils (EOS), and serum levels of immunoglobulin E (IgE) and amyloid protein (SAA) in the two groups before and after treatment were observed and compared. And the adverse reactions of the two groups were statistically recorded. Results The total effective rate was higher in the observation group than in the control group [93.18% (41/44) vs. 74.42% (32/43)], with a statistical difference (P 0.05) . Conclusion Leukotriene receptor antagonist combined with budesonide aerosol inhalation for children with cough variant asthma can improve their levels of EOS, SAA, and IgE and lung function. Besides, it is effective and safe. Key words: Cough variant asthma; Children; Leukotriene receptor antagonist; Aerosol budesonide; Pulmonary function